论文部分内容阅读
本文报告了冬虫夏草提取物CS-Ⅱ对小鼠艾氏腹水癌的抑制作用。每鼠腹腔接种5×10~5癌细胞,24小时后用CS-Ⅱ治疗,在0.355 g/kg×15、0.71 g/kg×15和1.42 g/kg×15的剂量下,生存延长率各为55.4％、97.4％和126.6％。肿瘤未发率各为40％、70％、70％,而对照为0％。另外于接癌前5天和后10天内,每天注射1.42g/kg CS-Ⅱ,经六次重复实验其生存延长率和肿瘤未发率均与对照有明显差异。本文还讨论了 CS-Ⅱ与Jagger等从Cordyceps militaris(L.)Link的培养液中分离的代谢产物冬虫夏草素的不同。
This article reports the inhibitory effect of Cordyceps sinensis extract CS-II on Ehrlich ascites carcinoma in mice. Each mouse was inoculated intraperitoneally with 5×10-5 cancer cells and treated with CS-II 24 hours later. The survival prolongation rate was 0.355 g/kg×15, 0.71 g/kg×15, and 1.42 g/kg×15. It was 55.4%, 97.4%, and 126.6%. The incidence of tumors was 40%, 70%, and 70%, respectively, whereas the control was 0%. In addition, 1.42 g/kg of CS-II was injected daily 5 days before and 5 days after receiving cancer. The survival rate and the rate of tumor failure in the six replicates were significantly different from the control. This article also discusses the differences between CS-II and Jagger, metabolites of Cordyceps sinensis isolated from Cordyceps militaris (L.) Link.